Company: BFRG
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023560
Chunk: 7

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 7
---

bfLEAP™, is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (“JHU-APL”),
which the Company believes is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians
by providing a more precise, multi-dimensional understanding of their data. The Company is deploying its analytical platform, including
bfLEAP™, for use in several critical stages of development of internal programs and through strategic partnerships and collaborations
with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing
failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need.

The
proprietary analytical platform utilizes both supervised and unsupervised machine learning. As such, it is able to reveal real and meaningful
connections in the data without the need for a priori hypothesis. Algorithms used in the platform are designed to handle highly imbalanced
data sets and successfully identify combinations of factors that are associated with outcomes of interest. The Company’s platform
leverages models that use both correlative and causative machine learning and artificial intelligence approaches which provide a comprehensive
approach to predictive analysis that is expected to lead to meaningful insights including the molecular drivers of disease. In this regard,
with the Company’s access to proprietary data sets such as its strategic data and commercialization agreements with the Lieber
Institute for Brain Development (“LIBD”), the Company has increased its internal efforts on target discovery.

The
Company’s goal is to improve the odds of success at all stages of pre-clinical and clinical therapeutics development for in-house
programs and for its strategic partners, collaborators, and customers. The Company’s business model includes enabling the success
of ongoing clinical trials and rescuing late stage failed drugs (i.e., Phase II or Phase III clinical trial failures) by bringing them
in-house for development prior to eventual divestiture; although, the Company also considers entering collaborations for earlier stage
drugs. The Company pursues its drug asset enhancement business by leveraging the powerful and proven bfLEAP™ AI/ML platform initially
developed at JHU-APL. The Company believes the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical
and clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical
trial settings.

Liquidity
and Going Concern 

The
Company has